Market Research Logo

Essential Tremor - Pipeline Review, H2 2016

Essential Tremor - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Tremor – Pipeline Review, H2 2016, provides an overview of the Essential Tremor (Central Nervous System) pipeline landscape.

Essential tremor is a type of involuntary shaking movement in which no cause can be identified. Involuntary means you shake without trying to do so. Essential tremor is the most common type of tremor. The exact cause for essential tremor is unknown. Tremors occur when there is a problem with the nerves that supply certain muscles. The tremor is more likely to be noticed in the hands, but may affect the arms, head, eyelids, or other muscles. The tremor rarely affects the legs or feet. Treatment may not be needed unless the tremors interfere with your daily activities or cause embarrassment.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Tremor – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Essential Tremor (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Tremor (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 2, 2 and 2 respectively.Essential Tremor.

Essential Tremor (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Tremor (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Essential Tremor (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Tremor (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Tremor (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Tremor (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Tremor (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Tremor (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Essential Tremor Overview
Therapeutics Development
Pipeline Products for Essential Tremor - Overview
Essential Tremor - Therapeutics under Development by Companies
Essential Tremor - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Essential Tremor - Products under Development by Companies
Essential Tremor - Companies Involved in Therapeutics Development
Merz Pharma GmbH & Co KgaA
Neurocrine Biosciences Inc
Sage Therapeutics Inc
Essential Tremor - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
incobotulinumtoxin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBI-640756 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAGE-217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Essential Tremor - Dormant Projects
Essential Tremor - Discontinued Products
Essential Tremor - Product Development Milestones
Featured News & Press Releases
Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting
Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline
Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor
Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Essential Tremor, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Essential Tremor - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2016
Essential Tremor - Pipeline by Neurocrine Biosciences Inc, H2 2016
Essential Tremor - Pipeline by Sage Therapeutics Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Essential Tremor - Dormant Projects, H2 2016
Essential Tremor - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Essential Tremor, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report